References
1. Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A,
Jedrzejczak-Czechowicz M, Doan S, Marmouz F, Demoly P, Delgado L. Ocular
allergy: recognizing and diagnosing hypersensitivity disorders of the
ocular surface. Allergy 2012;67:1327-1337.
2. Sheldrick JH, Wilson AD, Vernon SA, Sheldrick CM. Management of
ophthalmic dis-ease in general practice. Br J Gen Pract
1993;43(376):459-62.
3. Manners T. Managing eye conditions in general practice. BMJ 1997;315:
816-817
4. Bielory L, Skoner DP, Blaiss MS, Leatherman B, Dykewicz MS, Smith N,
Ortiz G, Had-ley JA, Walstein N, Craig TJ, Allen-Ramey F. Ocular and
nasal allergy symptom burden in America: the Allergies, Immunotherapy,
and Rhinoconjunctivitis (AIRS) surveys. Allergy Asthma Proc 2014
May-Jun;35(3):211-8.
5. Bousquet J, Khaltaev N, Cruz AA, et al: Allergic Rhinitis and its
Impact on Asthma (ARIA) 2008 update [in collaboration with the World
Health Organization, GA(2)LEN and Al-lerGen]. Allergy 2008;
63(86):8-160.
6. Eriksson NE, Holmen A: Skin prick tests with standardized extracts of
inhalant aller-gens in 7,099 adult patients with asthma or rhinitis:
cross-sensitizations and relationships to age, sex, month of birth and
year of testing. J Investig Allergol Clin Immunol 1996;6:36-46.
7. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D:
Geographical varia-tion in the prevalence of positive skin tests to
environmental aeroallergens in the European Community Respiratory Health
Survey I. Allergy 2007;62: 301-309.
8. Pfaar O, Karatzas K, Bastl K, et al. Pollen season is reflected on
symptom load for grass and birch pollen-induced allergic rhinitis in
different geographic areas—An EAACI Task Force Report. Allergy
2020;75:1099-1106.
9. Caillaud D, Martin S, Segala C, Besancenot J-P, Clot B, Thibaudon M.
Effects of air-borne birch pollen levels on clinical symptoms of
seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol
2014;163:43-50.
10. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge.
A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol
1990 jan;108(1):84‑8.
11. Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, Calder V, Silva D,
Kvenshagen BK, et al. Conjunctival allergen provocation test: guidelines
for daily practice. Allergy 2017;72(1):43-54.
12. Horak F, Berger UE, Menapace R, Toth J, Stübner PU, Marks B.
Dose-dependent pro-tection by azelastine eye drops against
pollen-induced allergic conjunctivitis. A double-blind,
placebo-controlled study. Arzneimittelforschung 1998;48:379-384.
13. Horak F, Stübner P, Zieglmayer R, Kawina A, Moser M, Lanz R. Onset
and duration of action of ketotifen 0.025% and emedastine 0.05% in
seasonal allergic conjunctivitis: efficacy after repeated pollen
challenges in the Vienna challenge chamber. Clin Drug Investig
2003;23:329-323.
14. Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke
JH, et al. Al-lergen exposure chambers: harmonizing current concepts and
projecting the needs for the future - an EAACI Position Paper. Allergy
2017;72(7):1035-1042.
15. Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure
chambers in aller-gen immunotherapy trials: Current status and clinical
validation needs. J Allergy Clin Immu-nol 2015;135:636‑643.
16. Khayath N, Doyen V, Gherasim A, Radu C, Choual I, Beck N, Jacob A,
Schoettel F, Ve-cellio L, Domis N, de Blay F. Validation of Strasbourg
environmental exposure chamber (EEC) ALYATEC in mite allergic subjects
with asthma. J Asthma 2020 Feb;57(2):140-148.
17. Gherasim A, Jacob A, Schoettel F, Domis N, de Blay F. Efficacy of
air cleaners in asthmatics allergic to cat in ALYATEC® environmental
exposure chamber. Clin Exp Aller-gy.2020 Feb;50(2):160-169.
18. Baudoin C. Formes frontières de l’allergie. [Neighboring forms of
allergy]. J Fr. Oph-talmol, 2007;30(3):306-313.
19. Bertel F, Mortemousque B, Sicard H, André C. Test de provocation
conjonctivale au Dermatophagoïdes pteronyssinus dans le diagnostic des
conjonctivites allergiques aux aca-riens domestiques [Conjunctival
provocation test with Dermatophagoides pteronyssinus in the diagnosis of
allergic conjunctivitis from house mites]. J Fr Ophtalmol. 2001
Jun;24(6):581-9.
20. Buters J. T.M, Thibaudon M, Smith M, Kennedy R, Rantio-Lehtimäki A,
Albertini R, Reese G, Weber B, Galan C, Brandao R, Antunes CM, Jäger S,
Berger U, Celenk S, Grewling Ł, Jackowiak B, Sauliene I, Weichenmeier I,
Pusch G, Sarioglu H, Ueffing M, Behrendt H, Prank M, Sofiev M, Cecchi L.
The HIALINE working group. Release of Bet v 1 from birch pol-len from 5
European countries. Results from the HIALINE study. Atmospheric
Environment 2012, 55:496-505.
21. Prince A, Norris MR, Bielory L. Seasonal ocular allergy and pollen
counts. Curr Opin Allergy Clin Immunol 2018 Oct;18(5):387-392.
22. Jacobs RL, Ramirez DA, Rather CG, Andrews CP, Jupiter DC, Trujillo
F, et al. Redness response phenotypes of allergic conjunctivitis in an
allergen challenge chamber. Ann Allergy Asthma Immunol 2017;
118(1):86-93.
23. Patel D, Garadi R, Brubaker M, Conroy JP, Kaji Y, Crenshaw K, et al.
Onset and dura-tion of action of nasal sprays in seasonal allergic
rhinitis patients: olopatadine hydrochloride versus mometasone furoate
monohydrate. Allergy Asthma Proc 2007; 28:592-9.
24. Ellis AK, Ratz JD, Day AG, Day JH. Factors that affect the allergic
rhinitis response to ragweed allergen exposure. Ann Allergy Asthma
Immunol 2010; 104:293-298.
25. Day JH, Brisoce MP. Environmental exposure unit: a system to test
anti-allergic treatment. Ann Allergy Asthma Immunol 1999; 83:83-93.
26. Zieglmayer P. Are results of environmental exposure units
transferable to real-life exposure? Curr Opin Allergy Clin Immunol 2013,
13:244–2480.028.